With the approval of the IND application, Harbour Med will accelerate the phase I global multi-center clinical trial of HBM7008.
Harbour Med (Chinese: 和铂医药, 02142. HK) announced that its product HBM7008, a bispecific antibody, obtained an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA).
HBM7008 is a bi-functional protein targeting dual tumor associated antigen B7H4 and 4-1BB. It has significant efficacy in T cell co-stimulation and tumor growth inhibition and is expected to have a better curative effect in patients has failed PD-1 or PD-L1 treatment.
The product was also approved to carry out a phase I clinical trial for the solid tumor in Australia on February 28th this year and the clinical application was accepted by the Center For Drug Evaluation (CDE) one month later in China.
Harbour Med is a global biopharmaceutical enterprise focusing on the R&D and commercialization of innovative drugs in the field of cancer and immune diseases. The company has rapidly expanded the innovative drugs pipeline through independent R&D, joint development and diversified cooperation modes.
Oncology and Immuno-Oncology Product Pipeline of Harbour Med (Source: Official Website)
Chinese pharma that produces bispecific antibodies includes Innoventbio (Chinese: 信达生物)， Beigene (Chinese: 百济神州), Zai Lab (Chinese: 再鼎医药) and so on.